Based on your results, you may want to discuss your bladder symptoms with your physician to see if the Altaviva™ implant or other treatment options would help you with your symptoms. Please check your email for your survey results and additional resources.

The Altaviva™ implant is a treatment option for UUI, but it may not be available through all physicians at this time. We’ll notify you via email when there are physicians in your area who can implant the Altaviva™ device.

Frequently Asked Questions

The Altaviva™ implant for UUI involves placing a small device under the skin near your ankle, which sends electrical pulses to the tibial nerve that helps maintain normal bladder function.1,2 These pulses may help restore the communication pathway between your brain and bladder which may help urgency with leaks.3 This treatment is called tibial neuromodulation, a proven therapy for reducing bladder control symptoms.3-8

Altaviva™ implant works by sending electrical pulses to the tibial nerve, which is linked to the nerves that control your bladder. These pulses may help restore the communication pathway between your brain and bladder,1,2 which may help reduce urgency, frequency, and leaks.3

Bladder control issues often stem from miscommunication between the brain and the nerves controlling bladder function.9,10 By targeting the tibial nerve, the therapy can help restore normal bladder function.3

The device needs to be charged 1–2 times per year under standard therapy settings and charging only takes about 30 minutes with proper placement and default recharge speed.

In addition to risks related to surgery, complications can include pain at the implant site, lower leg pain, infection, technical or device problems, movement of the implant, undesirable change in bowel or bladder function, or uncomfortable or unintended stimulation sensations. Please see Important Safety Information for more details. Talk with your doctor about ways to minimize these risks.

Urge urinary incontinence is a chronic condition. Altaviva™ therapy can help manage the symptoms but does not cure the condition.

The implant has a long-lasting battery11 expected to deliver 15 years of therapy.

The procedure is minimally invasive,12 requiring a 2 cm incision.

You can have a full-body MRI scan if certain conditions are met.13 Your clinician can provide more details about these conditions, as well as safety information.

Talk to your doctor and your insurance provider to learn more about your coverage.

Prospective patients, reach an education specialist: (800) 664-5111

Existing patients, reach a service specialist: (800) 510-6735.

  1. Li X, Li X, Liao L. Mechanism of action of tibial nerve stimulation in the treatment of lower urinary tract dysfunction. Neuromod. 2023;27:256-266.
  2. Bhide AA, Tailor V, Fernando R, Vik K, Digesu GA. Posterior tibial nerve stimulation for overactive bladder - techniques and efficacy. Int Urogynecol J. 2020;31:865-70.
  3. Appendix B: Clinical Study Summary. M028929C001 RevC - Clinician Therapy and Programming Guide Altaviva™ Model P7850N.
  4. Peters KM, Carrico DJ, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438-1443.
  5. Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055-1061.
  6. Kobashi K, Nitti V, Margolis E, et al. A prospective study to evaluate efficacy using the NURO percutaneous tibial neuromodulation system in drug-naïve patients with overactive bladder syndrome. J Urol. 2019;131:77-82.
  7. Rogers A, Bragg S, Ferrante K, et al. Pivotal study of leadless tibial nerve stimulation with eCoin for urgency urinary incontinence: an open-label, single arm trial. J Urol. 2021;206:399-408.
  8. Heesakkers JPFA, Toozs-Hobson P, Sutherland SE, et al. A prospective study to assess the effectiveness and safety of the BlueWind system in the treatment of patients diagnosed with urgency urinary incontinence. Neurourol Urodyn. 2024;43:1491-1503.
  9. Chancellor MB, Chartier-Kastler EJ. Principles of sacral nerve stimulation (SNS) for the treatment of bladder and urethral sphincter dysfunctions. Neuromod. 2000;3(1):15-26.
  10. Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11-18.
  11. M028929C001 RevC - Clinician Therapy and Programming Guide Altaviva™ Model P7850N
  12. Cameron AP, Chung DE, Dielubanza EJ et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder (2024). J Urol. 2024;212:11-20.
  13. M028949C001 RevC - MRI Guidelines for Altaviva™ Neurostimulator